This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Brazilian health agency queried by CADE in review of União Química-Bayer deal

By Maria Júlia Baumert ( November 8, 2024, 23:07 GMT | Insight) -- Brazil’s competition authority has queried the Brazilian Health Regulatory Agency (Anvisa) regarding União Química Farmacêutica Nacional's proposed acquisition of manufacturing, commercialization, and intellectual property rights for the hormonal therapy drugs Primogyna and Cicloprimogyna from Bayer AG. Anvisa has until Nov. 14 to respond.Brazil’s competition authority has queried the Brazilian Health Regulatory Agency (Anvisa) regarding União Química Farmacêutica Nacional's proposed acquisition of manufacturing, commercialization, and intellectual property rights for the hormonal therapy drugs Primogyna and Cicloprimogyna from Bayer AG. Anvisa has until Nov. 14 to respond.The Administrative Council for Economic Defense, or CADE, wants Anvisa to confirm the information provided by the companies about these drugs. They are seeking clarification on the therapeutic indications of the drugs, along with their market share. CADE also asked if there are substitute drugs manufactured by Bayer and União Química and sought information on the market share of these alternatives....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login